- What other names is Copper known by?
- What is Copper?
- How does Copper work?
- Are there safety concerns?
- Are there any interactions with medications?
- Dosing considerations for Copper.
Atomic number 29, Citrate de Cuivre, Cobre, Copper Citrate, Copper Gluconate, Copper Sulfate, Cu, Cuivre, Cuivre Élémentaire, Cupric Oxide, Cupric Sulfate, Cupric Sulfate Pentahydrate, Cuprum Aceticum, Cuprum Metallicum, Elemental Copper, Gluconate de Cuivre, Numéro Atomique 29, Oxyde Cuivrique, Pentahydrate de Sulfate de Cuivre, Sulfate de Cuivre, Sulfate Cuivrique, Sulfate Cuprique.
Copper is a mineral. It is found in many foods, particularly in organ meats, seafood, nuts, seeds, wheat bran cereals, grain products, and cocoa products. The body stores copper mostly in the bones and muscles. The liver regulates the amount of copper that is in the blood. Copper is used as medicine.
Copper is used for treating copper deficiency and the anemia it may cause. Having too little copper (copper deficiency) is rare. It sometimes occurs in people who get too much zinc from diet or supplements, have intestinal bypass surgery, or are fed by feeding tubes. Malnourished infants can also have copper deficiency.
There is no evidence that people who eat a normal diet need copper supplements. Not even athletes need extra copper if they have a good diet.
Likely Effective for...
- Copper deficiency. Taking copper by mouth at recommended levels or given intravenously (by IV) by a healthcare provider is effective for treating copper deficiency and anemia caused by copper deficiency.
Possibly Ineffective for...
- Alzheimer's disease. Research suggests that taking copper by mouth daily for 12 months does not improve symptoms of Alzheimer's disease.
- Diarrhea. Young children with severe diarrhea due to a gut infection do not seem to be helped by taking copper.
- Lupus. Taking copper daily, alone or together with fish oil, does not seem to improve symptoms of a type of lupus called system lupus erythematosus.
Insufficient Evidence to Rate Effectiveness for...
- Acne. Some early research suggests that taking a product containing copper and several other ingredients (NicAzel, Elorac, Inc) might reduce a severe form of acne.
- Dental plaque. Early research suggests that rinsing the mouth with a copper solution decreases plaque.
- Osteoporosis. Some early research shows that taking copper in combination with zinc, manganese, and calcium might slow bone loss in older women.
- Wound healing.
- Other conditions.
Copper is necessary for producing and storing iron. Copper is also involved in many of natural processes in the body.
Copper is LIKELY SAFE when taken by mouth in amounts no greater than 10 mg daily.
Copper is POSSIBLY UNSAFE when taken by mouth in large amounts. Adults should consume no more than 10 mg of copper per day. Kidney failure and death can occur with as little as 1 gram of copper sulfate. Symptoms of copper overdose include nausea, vomiting, bloody diarrhea, fever, stomach pain, low blood pressure, anemia, and heart problems.
Special Precautions & Warnings:Pregnancy and breast-feeding: Copper is LIKELY SAFE when taken by mouth appropriately. Pregnant or breast-feeding women should consume no more than 8 mg dailyper day if they are 14 to 18 years old, and no more than 10 mg dailyper day if they are 19 or older. Taking copper by mouth in higher doses is POSSIBLY UNSAFE. Higher amounts can be dangerous.
Children: Copper is LIKELY SAFE when taken by mouth appropriately. Children should not get more than the Tolerable Upper Limit (UL) of copper. The UL is 1 mg daily for children 1 to 3 years, 3 mg daily for children 4 to 8 years, 5 mg daily for children 9 to 13 years, and 8 mg daily for adolescents. Taking copper by mouth in higher doses is POSSIBLY UNSAFE. Higher intake can cause liver damage and other harm.
Hemodialysis: People receiving hemodialysis for kidney disease seem to be at risk for copper deficiency. You might need copper supplements if you are undergoing hemodialysis. Check with your healthcare provider.
Certain hereditary conditions, including idiopathic copper toxicosis and childhood cirrhosis: Taking extra copper might make these conditions worse.
Wilson's disease: Taking copper supplements can make this condition worse and might interfere with treatment.
Penicillamine (Cuprimine, Depen)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Penicillamine is used for Wilson's disease and rheumatoid arthritis. Copper might decrease how much penicillamine your body absorbs and decrease the effectiveness of penicillamine.
The following doses have been studied in scientific research:
- For low levels of copper (copper deficiency): doses up to 0.1 mg/kg of cupric sulfate per day.
- For osteoporosis: 2.5 mg copper combined with zinc 15 mg, 5 mg manganese, and 1000 mg calcium per day.
For men and women age 19 years and older, the RDA of copper is 900 mcg/day.
The Tolerable Upper Intake Level (UL), the maximum amount for which no harmful effect is expected, has been established for children and adults. The ULs for copper are: children 1 to 3 years, 1 mg/day; 4 to 8 years, 3 mg/day; 9 to 13 years, 5 mg/day; 14 to 18 years (including pregnancy and lactation) 8 mg/day; adults age 19 and older (including breast feeding), 10 mg/day; pregnancy age 19 and older, 8 mg/day.
- Healthcare providers give copper intravenously (by IV) for copper deficiency.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors
Abdullah, A. Z., Strafford, S. M., Brookes, S. J., and Duggal, M. S. The effect of copper on demineralization of dental enamel. J Dent Res 2006;85(11):1011-1015. View abstract.
Araya, M., McGoldrick, M. C., Klevay, L. M., Strain, J. J., Robson, P., Nielsen, F., Olivares, M., Pizarro, F., Johnson, L. A., and Poirier, K. A. Determination of an acute no-observed-adverse-effect level (NOAEL) for copper in water. Regul.Toxicol.Pharmacol. 2001;34(2):137-145. View abstract.
Araya, M., Olivares, M., Pizarro, F., Llanos, A., Figueroa, G., and Uauy, R. Community-based randomized double-blind study of gastrointestinal effects and copper exposure in drinking water. Environ.Health Perspect. 2004;112(10):1068-1073. View abstract.
Ashkenazi, A., Levin, S., Djaldetti, M., Fishel, E., and Benvenisti, D. The syndrome of neonatal copper deficiency. Pediatrics 1973;52(4):525-533. View abstract.
August, D., Janghorbani, M., and Young, V. R. Determination of zinc and copper absorption at three dietary Zn-Cu ratios by using stable isotope methods in young adult and elderly subjects. Am J Clin Nutr 1989;50(6):1457-1463. View abstract.
Baker, A., Harvey, L., Majask-Newman, G., Fairweather-Tait, S., Flynn, A., and Cashman, K. Effect of dietary copper intakes on biochemical markers of bone metabolism in healthy adult males. Eur.J.Clin.Nutr. 1999;53(5):408-412. View abstract.
Baker, A., Turley, E., Bonham, M. P., O'Connor, J. M., Strain, J. J., Flynn, A., and Cashman, K. D. No effect of copper supplementation on biochemical markers of bone metabolism in healthy adults. Br.J.Nutr. 1999;82(4):283-290. View abstract.
BAKWIN, R. M. Ceruloplasmin activity and copper levels in the serum of children with schizophrenia. J Am Med Womens Assoc 1961;16:522-523. View abstract.
BAKWIN, R. M., MOSBACH, E. H., and BAKWIN, H. Concentration of copper in serum of children with schizophrenia. Pediatrics 1961;27:642-644. View abstract.
Bonham, M., O'Connor, J. M., McAnena, L. B., Walsh, P. M., Downes, C. S., Hannigan, B. M., and Strain, J. J. Zinc supplementation has no effect on lipoprotein metabolism, hemostasis, and putative indices of copper status in healthy men. Biol.Trace Elem.Res. 2003;93(1-3):75-86. View abstract.
Bowman, M. B. and Lewis, M. S. The copper hypothesis of schizophrenia: a review. Neurosci.Biobehav.Rev 1982;6(3):321-328. View abstract.
Brown, N. A., Bron, A. J., Harding, J. J., and Dewar, H. M. Nutrition supplements and the eye. Eye 1998;12 ( Pt 1):127-133. View abstract.
Bugel, S., Harper, A., Rock, E., O'Connor, J. M., Bonham, M. P., and Strain, J. J. Effect of copper supplementation on indices of copper status and certain CVD risk markers in young healthy women. Br.J Nutr 2005;94(2):231-236. View abstract.
Burdeinyi, A. F. [Levels of copper and zinc in the blood of patients with various types of schizophrenia]. Zh.Nevropatol.Psikhiatr.Im S.S.Korsakova 1967;67(7):1041-1043. View abstract.
Bureau, I., Lewis, C. G., and Fields, M. Effect of hepatic iron on hypercholesterolemia and hypertriacylglycerolemia in copper-deficient fructose-fed rats. Nutrition 1998;14(4):366-371. View abstract.
Cashman, K. D., Baker, A., Ginty, F., Flynn, A., Strain, J. J., Bonham, M. P., O'Connor, J. M., Bugel, S., and Sandstrom, B. No effect of copper supplementation on biochemical markers of bone metabolism in healthy young adult females despite apparently improved copper status. Eur.J.Clin.Nutr. 2001;55(7):525-531. View abstract.
Castillo-Duran, C., Fisberg, M., Valenzuela, A., Egana, J. I., and Uauy, R. Controlled trial of copper supplementation during the recovery from marasmus. Am.J.Clin.Nutr. 1983;37(6):898-903. View abstract.
Chitre, V. S. and Punekar, B. D. Changes in serum copper and PPD-oxidase in different diseases. II. Comparative studies in Wilson's disease schizophrenia and Parkinsonism. Indian J Med Res 1970;58(5):563-573. View abstract.
Christodoulou, J., Danks, D. M., Sarkar, B., Baerlocher, K. E., Casey, R., Horn, N., Tumer, Z., and Clarke, J. T. Early treatment of Menkes disease with parenteral copper-histidine: long-term follow-up of four treated patients. Am J Med Genet. 3-5-1998;76(2):154-164. View abstract.
Chugh, T. D., Dhingra, R. K., Gulati, R. C., and Bathla, J. C. Copper metabolism in schizophrenia. Indian J Med Res 1973;61(8):1147-1152. View abstract.
Czeizel, A. E. and Dudas, I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl.J Med 12-24-1992;327(26):1832-1835. View abstract.
da Silveira, S. V., Canato, C., de Jorge, F. B., and Delascio, D. [Copper, iron, magnesium and sulfur in the serum of pregnant women with sideroblastic anemia before, during, and after parenteral iron infusion therapy]. Matern.Infanc.(Sao Paulo) 1967;26(3):269-273. View abstract.
DOGAN, S., KELER, M., and PERSIC, N. [Copper in blood in schizophrenia; a problem of pathophysiology of schizophrenia.]. Acta Med Iugosl. 1955;9(1):60-70. View abstract.
Fiske, D. N., McCoy, H. E., III, and Kitchens, C. S. Zinc-induced sideroblastic anemia: report of a case, review of the literature, and description of the hematologic syndrome. Am J Hematol. 1994;46(2):147-150. View abstract.
Freycon, F. and Pouyau, G. [Rare nutritional deficiency anemia: deficiency of copper and vitamin E]. Sem.Hop. 2-17-1983;59(7):488-493. View abstract.
George, D. H. and Casey, R. E. Menkes disease after copper histidine replacement therapy: case report. Pediatr Dev.Pathol. 2001;4(3):281-288. View abstract.
Gillin, J. C., Carpenter, W. T., Hambidge, K. M., Wyatt, R. J., and Henkin, R. I. Zinc and copper in patients with schizophrenia. Encephale 1982;8(3):435-444. View abstract.
Gorter, R. W., Butorac, M., and Cobian, E. P. Examination of the cutaneous absorption of copper after the use of copper-containing ointments. Am J Ther 2004;11(6):453-458. View abstract.
Gregg, X. T., Reddy, V., and Prchal, J. T. Copper deficiency masquerading as myelodysplastic syndrome. Blood 8-15-2002;100(4):1493-1495. View abstract.
Harvey, L. J., Majsak-Newman, G., Dainty, J. R., Lewis, D. J., Langford, N. J., Crews, H. M., and Fairweather-Tait, S. J. Adaptive responses in men fed low- and high-copper diets. Br J Nutr 2003;90(1):161-168. View abstract.
Henry, N. L., Dunn, R., Merjaver, S., Pan, Q., Pienta, K. J., Brewer, G., and Smith, D. C. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 2006;71(3-4):168-175. View abstract.
Herran, A., Garcia-Unzueta, M. T., Fernandez-Gonzalez, M. D., Vazquez-Barquero, J. L., Alvarez, C., and Amado, J. A. Higher levels of serum copper in schizophrenic patients treated with depot neuroleptics. Psychiatry Res 4-24-2000;94(1):51-58. View abstract.
Humphries, W. R., Phillippo, M., Young, B. W., and Bremner, I. The influence of dietary iron and molybdenum on copper metabolism in calves. Br.J.Nutr. 1983;49(1):77-86. View abstract.
Institute of Medicine ed. Food and Nutrition Board. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc (2000). National Academy Press;2000.
Irving, J. A., Mattman, A., Lockitch, G., Farrell, K., and Wadsworth, L. D. Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. CMAJ. 7-22-2003;169(2):129-131. View abstract.
Jendryczko, A., Drozdz, M., and Magner, K. Antilupus activity of copper (II). Exp Pathol. 1985;28(3):187-189. View abstract.
Kappel, L. C., Ingraham, R. H., Morgan, E. B., and Babcock, D. K. Plasma copper concentration and packed cell volume and their relationships to fertility and milk production in Holstein cows. Am.J.Vet.Res. 1984;45(2):346-350. View abstract.
Kelley, D. S., Daudu, P. A., Taylor, P. C., Mackey, B. E., and Turnlund, J. R. Effects of low-copper diets on human immune response. Am.J.Clin.Nutr. 1995;62(2):412-416. View abstract.
Kessler, H., Bayer, T. A., Bach, D., Schneider-Axmann, T., Supprian, T., Herrmann, W., Haber, M., Multhaup, G., Falkai, P., and Pajonk, F. G. Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. J Neural Transm. 2008;115(8):1181-1187. View abstract.
Kimura, A., Yoshino, H., and Yuasa, T. [A case of cerebellar degeneration with schizophrenia-like psychosis, severe iron deficiency, hypoceruloplasminemia and abnormal electroretinography: a new syndrome?]. Rinsho Shinkeigaku 2001;41(8):507-511. View abstract.
Kirodian, B. G., Gogtay, N. J., Udani, V. P., and Kshirsagar, N. A. Treatment of Menkes disease with parenteral copper histidine. Indian Pediatr 2002;39(2):183-185. View abstract.
Klevay, L. M. Interactions of copper and zinc in cardiovascular disease. Ann.N.Y.Acad.Sci. 1980;355:140-151. View abstract.
Klevay, L. M. The influence of copper and zinc on the occurrence of ischemic heart disease. J.Environ.Pathol.Toxicol. 1980;4(2-3):281-287. View abstract.
Klevay, L. M., Reck, S. J., Jacob, R. A., Logan, G. M., Jr., Munoz, J. M., and Sandstead, H. H. The human requirement for copper. I. Healthy men fed conventional, American diets. Am.J.Clin.Nutr. 1980;33(1):45-50. View abstract.
KOEGLER, R. R., COLBERT, E. G., and EIDUSON, S. Wanted: a biochemical test for schizophrenia. Calif.Med 1961;94:26-29. View abstract.
KOLAKOWSKA, T., SZAJBEL, W., and MURAWSKI, K. [Serum ceruloplasmin and copper in schizophrenia.]. Neurol.Neurochir.Psychiatr.Pol. 1960;10:691-696. View abstract.
Kreuder, J., Otten, A., Fuder, H., Tumer, Z., Tonnesen, T., Horn, N., and Dralle, D. Clinical and biochemical consequences of copper-histidine therapy in Menkes disease. Eur J Pediatr 1993;152(10):828-832. View abstract.
Kumar, A. and Jazieh, A. R. Case report of sideroblastic anemia caused by ingestion of coins. Am J Hematol. 2001;66(2):126-129. View abstract.
Lei, K. Y. Oxidation, excretion, and tissue distribution of [26-14C] cholesterol in copper-deficient rats. J.Nutr. 1978;108(2):232-237. View abstract.
MAAS, J. W., GLESER, G. C., and GOTTSCHALK, L. A. Schizophrenia, anxiety, and biochemical factors. The rate of oxidation of N, N-dimethyl-p-phenylenediamine by plasma and levels of serum copper and plasma ascorbic acid. Arch Gen.Psychiatry 1961;4:109-118. View abstract.
May, A. and Fitzsimons, E. Sideroblastic anaemia. Baillieres Clin Haematol. 1994;7(4):851-879. View abstract.
Miller, T. R., Wagner, J. D., Baack, B. R., and Eisbach, K. J. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial.Plast.Surg 2006;8(4):252-259. View abstract.
Munakata, M., Sakamoto, O., Kitamura, T., Ishitobi, M., Yokoyama, H., Haginoya, K., Togashi, N., Tamura, H., Higano, S., Takahashi, S., Ohura, T., Kobayashi, Y., Onuma, A., and Iinuma, K. The effects of copper-histidine therapy on brain metabolism in a patient with Menkes disease: a proton magnetic resonance spectroscopic study. Brain Dev. 2005;27(4):297-300. View abstract.
MUNCH-PETERSEN, S. On serum copper in patients with schizophrenia. Acta Psychiatr.Neurol. 1951;25(4):423-427. View abstract.
O'Donohue, J., Reid, M., Varghese, A., Portmann, B., and Williams, R. A case of adult chronic copper self-intoxication resulting in cirrhosis. Eur J Med Res 6-28-1999;4(6):252. View abstract.
Olatunbosun, D. A., Akindele, M. O., Adadevoh, B. K., and Asuni, T. Serum copper in schizophrenia in Nigerians. Br J Psychiatry 1975;127:119-121. View abstract.
OZEK, M. [Research on copper metabolism in several forms of schizophrenia.]. Arch Psychiatr.Nervenkr.Z Gesamte Neurol.Psychiatr. 1957;195(4):408-423. View abstract.
Patel, A., Dibley, M. J., Mamtani, M., Badhoniya, N., and Kulkarni, H. Zinc and copper supplementation in acute diarrhea in children: a double-blind randomized controlled trial. BMC.Med 2009;7:22. View abstract.
Patterson, W. P., Winkelmann, M., and Perry, M. C. Zinc-induced copper deficiency: megamineral sideroblastic anemia. Ann Intern Med 1985;103(3):385-386. View abstract.
Perry, A. R., Pagliuca, A., Fitzsimons, E. J., Mufti, G. J., and Williams, R. Acquired sideroblastic anaemia induced by a copper-chelating agent. Int J Hematol. 1996;64(1):69-72. View abstract.
Porea, T. J., Belmont, J. W., and Mahoney, D. H., Jr. Zinc-induced anemia and neutropenia in an adolescent. J Pediatr 2000;136(5):688-690. View abstract.
Puzynski, S. [Studies of the significance of disturbances in the metabolism of copper, ceruloplasmin and ascorbic acid in the pathogenesis of schizophrenia]. Rocz.Akad.Med Im Juliana Marchlewskiego Bialymst. 1969;14:99-162. View abstract.
Rahman, B., Rahman, M. A., and Hassan, Z. Copper and caeruloplasmin in schizophrenia. Biochem Soc Trans 1976;4(6):1138-1139. View abstract.
Ramadurai, J., Shapiro, C., Kozloff, M., and Telfer, M. Zinc abuse and sideroblastic anemia. Am J Hematol. 1993;42(2):227-228. View abstract.
Rhee, Y. S., Hermann, J. R., Burnham, K., Arquitt, A. B., and Stoecker, B. J. The effects of chromium and copper supplementation on mitogen-stimulated T cell proliferation in hypercholesterolaemic postmenopausal women. Clin.Exp.Immunol. 2002;127(3):463-469. View abstract.
Rivera Bandres J. [On some recently well-known anemias]. Rev Esp.Enferm.Apar.Dig 1966;25(8):942-958. View abstract.
Rodriguez, E. and Diaz, C. Iron, copper and zinc levels in urine: relationship to various individual factors. J Trace Elem.Med Biol 1995;9(4):200-209. View abstract.
Sarkar, B., Lingertat-Walsh, K., and Clarke, J. T. Copper-histidine therapy for Menkes disease. J Pediatr 1993;123(5):828-830. View abstract.
Shackel, N. A., Day, R. O., Kellett, B., and Brooks, P. M. Copper-salicylate gel for pain relief in osteoarthritis: a randomised controlled trial. Med J Aust. 8-4-1997;167(3):134-136. View abstract.
Sheela, S. R., Latha, M., Liu, P., Lem, K., and Kaler, S. G. Copper-replacement treatment for symptomatic Menkes disease: ethical considerations. Clin Genet. 2005;68(3):278-283. View abstract.
Sheth, S. and Brittenham, G. M. Genetic disorders affecting proteins of iron metabolism: clinical implications. Annu Rev Med 2000;51:443-464. View abstract.
Shore, D., Potkin, S. G., Weinberger, D. R., Torrey, E. F., Henkin, R. I., Agarwal, R. P., Gillin, J. C., and Wyatt, R. J. CSF copper concentrations in chronic schizophrenia. Am J Psychiatry 1983;140(6):754-757. View abstract.
Silverstone, B. Z., Landau, L., Berson, D., and Sternbuch, J. Zinc and copper metabolism in patients with senile macular degeneration. Ann.Ophthalmol. 1985;17(7):419-422. View abstract.
Simon, S. R., Branda, R. F., Tindle, B. F., and Burns, S. L. Copper deficiency and sideroblastic anemia associated with zinc ingestion. Am J Hematol. 1988;28(3):181-183. View abstract.
Skalski, M. [Disorders of copper metabolism]. Wiad.Lek. 8-15-1986;39(16):1120-1123. View abstract.
Sorenson, J. R. Evaluation of copper complexes as potential anti-arthritic drugs. J Pharm Pharmacol 1977;29(7):450-452. View abstract.
Strain, J. J. A reassessment of diet and osteoporosis--possible role for copper. Med Hypotheses 1988;27(4):333-338. View abstract.
Tashiro, A., Satodate, R., and Segawa, I. Histological changes in cardiac hemochromatosis improved by an iron-chelating agent. A biopsy case. Acta Pathol Jpn. 1990;40(4):288-292. View abstract.
Tokdemir, M., Polat, S. A., Acik, Y., Gursu, F., Cikim, G., and Deniz, O. Blood zinc and copper concentrations in criminal and noncriminal schizophrenic men. Arch Androl 2003;49(5):365-368. View abstract.
Turnlund, J. R., Keyes, W. R., Kim, S. K., and Domek, J. M. Long-term high copper intake: effects on copper absorption, retention, and homeostasis in men. Am J Clin Nutr 2005;81(4):822-828. View abstract.
Tyrer, S. P., Delves, H. T., and Weller, M. P. CSF copper in schizophrenia. Am J Psychiatry 1979;136(7):937-939. View abstract.
Van Wouwe, J. P. and Veldhuizen, M. Growth characteristics in laboratory animals fed zinc-deficient, copper-deficient, of histidine-supplemented diets. Biol.Trace Elem.Res. 1996;55(1-2):71-77. View abstract.
Waler, S. M. and Rolla, G. Comparison between plaque inhibiting effect of chlorhexidine and aqueous solutions of copper- and silver-ions. Scand J Dent.Res 1982;90(2):131-133. View abstract.
Walker, W. R. and Keats, D. M. An investigation of the therapeutic value of the 'copper bracelet'-dermal assimilation of copper in arthritic/rheumatoid conditions. Agents Actions 1976;6(4):454-459. View abstract.
Weis, S., Haybaeck, J., Dulay, J. R., and Llenos, I. C. Expression of cellular prion protein (PrP(c)) in schizophrenia, bipolar disorder, and depression. J Neural Transm. 2008;115(5):761-771. View abstract.
Willis, M. S., Monaghan, S. A., Miller, M. L., McKenna, R. W., Perkins, W. D., Levinson, B. S., Bhushan, V., and Kroft, S. H. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol 2005;123(1):125-131. View abstract.
Wolf, T. L., Kotun, J., and Meador-Woodruff, J. H. Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia. Schizophr.Res 2006;86(1-3):167-171. View abstract.
Yamazaki, H., Fujieda, M., Togashi, M., Saito, T., Preti, G., Cashman, J. R., and Kamataki, T. Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients. Life Sci. 4-16-2004;74(22):2739-2747. View abstract.
Yanik, M., Kocyigit, A., Tutkun, H., Vural, H., and Herken, H. Plasma manganese, selenium, zinc, copper, and iron concentrations in patients with schizophrenia. Biol Trace Elem.Res 2004;98(2):109-117. View abstract.
Babic Z, Tariba B, Kovacic J, Pizent A, Varnai VM, Macan J. Relevance of serum copper elevation induced by oral contraceptives: a meta-analysis. Contraception. 2013 Jun;87(6):790-800. View abstract.
Baum MK, Javier JJ, Mantero-Atienza E, et al. Zidovudine-associated adverse reactions in a longitudinal study of asymptomatic HIV-1-infected homosexual males. J Acquir Immune Defic Syndr 1991;4:1218-26. View abstract.
Berger MM, Shenkin A, Revelly JP, et al. Copper, selenium, zinc, and thiamine balances during continuous venovenous hemodiafiltration in critically ill patients. Am J Clin Nutr 2004;80:410-6. View abstract.
Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998;132:264-78. View abstract.
Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA 1990;264:1441-3. View abstract.
Campbell IA, Elmes PC. Ethambutol and the eye: zinc and copper (letter). Lancet 1975;2:711. View abstract.
Campbell WW, Anderson RA. Effects of aerobic exercise and training on the trace minerals chromium, zinc and copper. Sports Med 1987 4:9-18. View abstract.
Cantilena LR, Klaassen CD. The effect of chelating agents on the excretion of endogenous metals. Toxicol Appl Pharmacol 1982;63:344-50. View abstract.
Clarkson PM, Haymes EM. Trace mineral requirements for athletes. Int J Sport Nutr 1994;4:104-19. View abstract.
Clarkson PM. Minerals: exercise performance and supplementation in athletes. J Sports Sci 1991;9:91-116. View abstract.
Cole A, May PM, Williams DR. Metal binding by pharmaceuticals. Part 1. Copper(II) and zinc(II) interactions following ethambutol administration. Agents Actions 1981;11:296-305. View abstract.
Domellöf M, Hernell O, Abrams SA, Chen Z, Lönnerdal B. Iron supplementation does not affect copper and zinc absorption in breastfed infants. Am J Clin Nutr. 2009 Jan;89(1):185-90. View abstract.
Duffy EM, Meenagh GK, McMillan SA, et al. The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol 2004;31:1551-6. View abstract.
Finley EB, Cerklewski FL. Influence of ascorbic acid supplementation on copper status in young adult men. Am J Clin Nutr 1983;37:553-6. View abstract.
Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002. Available at: www.nap.edu/books/0309072794/html/.
Gossel TA, Bricker JD. Principles of Clinical Toxicology. New York, NY:Raven Press, 1994.
Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.
Kozak SF, Inderlied CB, Hsu HY, et al. The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy. Diag Microbiol Infect Dis 1998;30:83-7. View abstract.
Lai H, Lai S, Shor-Posner G, et al. Plasma zinc, copper, copper:zinc ratio, and survival in a cohort of HIV-1-infected homosexual men. J Acquir Immune Defic Syndr Human Retrovirol 2001;27:56-62. View abstract.
Murry JJ, Healy MD. Drug-mineral interactions: a new responsibility for the hospital dietician. J Am Diet Assoc 1991;91:66-73. View abstract.
Nechifor M, Vaideanu C, Palamaru I, et al. The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia. J Am Coll Nutr 2004;23:549S-51S. View abstract.
Olivares M, Pizarro F, López de Romaña D, Ruz M. Acute copper supplementation does not inhibit non-heme iron bioavailability in humans. Biol Trace Elem Res. 2010 Aug;136(2):180-6. View abstract.
Pecanac M, Janjic Z, Komarcevic A, Pajic M, Dobanovacki D, Miskovic SS. Burns treatment in ancient times. Med Pregl. 2013 May-Jun;66(5-6):263-7. View abstract.
Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. Am J Clin Nutr 1995;61:621S-4S. View abstract.
Segal S, Kaminski S. Drug-nutrient interactions. American Druggist 1996 Jul;42-8.
Shalita AR, Falcon R, Olansky A, Iannotta P, Akhavan A, Day D, Janiga A, Singri P, Kallal JE. Inflammatory acne management with a novel prescription dietary supplement. J Drugs Dermatol. 2012;11(12):1428-33. View abstract.
Strause L, Saltman P, Smith KT, et al. Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals. J Nutr 1994;124:1060-4. View abstract.
Weight LM, Noakes TD, Labadarios D, et al. Vitamin and mineral status of trained athletes including the effects of supplementation. Am J Clin Nutr 1988;47:186-91. View abstract.